NCT03783442 2025-07-29
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
BeiGene
Ludwig Institute for Cancer Research
Fox Chase Cancer Center
Alliance for Clinical Trials in Oncology
Roswell Park Cancer Institute
Roswell Park Cancer Institute